Assenagon Asset Management S.A. Buys 45,701 Shares of Henry Schein, Inc. $HSIC

Assenagon Asset Management S.A. raised its position in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 212.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 67,181 shares of the company’s stock after purchasing an additional 45,701 shares during the quarter. Assenagon Asset Management S.A. owned 0.06% of Henry Schein worth $5,078,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the company. CYBER HORNET ETFs LLC purchased a new position in shares of Henry Schein during the 2nd quarter valued at $25,000. MUFG Securities EMEA plc purchased a new position in shares of Henry Schein in the second quarter valued at about $27,000. Sentry Investment Management LLC boosted its stake in shares of Henry Schein by 132.1% in the third quarter. Sentry Investment Management LLC now owns 905 shares of the company’s stock worth $59,000 after acquiring an additional 515 shares during the period. Mather Group LLC. purchased a new stake in shares of Henry Schein during the third quarter worth about $71,000. Finally, CX Institutional grew its position in shares of Henry Schein by 75.6% during the third quarter. CX Institutional now owns 1,143 shares of the company’s stock worth $76,000 after purchasing an additional 492 shares in the last quarter. 96.62% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, EVP Mark E. Mlotek sold 5,925 shares of the firm’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $80.80, for a total value of $478,740.00. Following the completion of the sale, the executive vice president owned 80,554 shares in the company, valued at approximately $6,508,763.20. This trade represents a 6.85% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Thomas C. Popeck sold 1,355 shares of Henry Schein stock in a transaction dated Thursday, March 19th. The stock was sold at an average price of $72.79, for a total transaction of $98,630.45. Following the transaction, the chief executive officer directly owned 86,182 shares of the company’s stock, valued at approximately $6,273,187.78. This represents a 1.55% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 105,911 shares of company stock valued at $8,574,982. 1.08% of the stock is currently owned by company insiders.

Henry Schein Trading Down 2.2%

Shares of HSIC stock opened at $72.10 on Friday. The company has a market cap of $8.27 billion, a PE ratio of 22.05, a price-to-earnings-growth ratio of 2.13 and a beta of 0.88. Henry Schein, Inc. has a 1 year low of $60.56 and a 1 year high of $89.29. The stock’s 50 day simple moving average is $77.37 and its two-hundred day simple moving average is $73.22. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.38 and a quick ratio of 0.76.

Henry Schein (NASDAQ:HSIC) last released its earnings results on Tuesday, February 24th. The company reported $1.34 earnings per share for the quarter, beating the consensus estimate of $1.30 by $0.04. Henry Schein had a return on equity of 15.16% and a net margin of 3.02%.The firm had revenue of $3.44 billion for the quarter, compared to the consensus estimate of $3.34 billion. During the same quarter in the previous year, the company posted $1.19 EPS. The company’s revenue for the quarter was up 7.7% compared to the same quarter last year. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. Research analysts predict that Henry Schein, Inc. will post 4.74 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on HSIC. UBS Group increased their price objective on shares of Henry Schein from $79.00 to $87.00 and gave the company a “neutral” rating in a report on Wednesday, February 25th. Robert W. Baird set a $100.00 target price on shares of Henry Schein and gave the stock an “outperform” rating in a report on Monday, February 23rd. Wall Street Zen lowered shares of Henry Schein from a “strong-buy” rating to a “buy” rating in a research report on Saturday, March 14th. Leerink Partners reaffirmed a “market perform” rating on shares of Henry Schein in a research note on Monday, March 9th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Henry Schein from $78.00 to $92.00 and gave the company an “overweight” rating in a report on Wednesday, February 25th. Six investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $85.58.

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.